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Many genetic variants associatedwith human disease have been found to be associatedwith alterations inmRNA expression. Although it
is commonly assumed thatmRNA expression changes will lead to consequent changes in protein levels, methodological challenges have
limited our ability to test the degree to which this assumption holds true. Here, we further developed the micro-western array approach
and globally examined relationships between human genetic variation and cellular protein levels. We collected more than 250,000 pro-
tein levelmeasurements comprising 441 transcription factor and signaling protein isoforms across 68 Yoruba (YRI) HapMap lymphoblas-
toid cell lines (LCLs) and identified 12 cis and 160 trans protein level QTLs (pQTLs) at a false discovery rate (FDR) of 20%.Whereas up to
two thirds of cismRNA expression QTLs (eQTLs) were also pQTLs, many pQTLs were not associated with mRNA expression. Notably, we
replicated and functionally validated a trans pQTL relationship between the KARS lysyl-tRNA synthetase locus and levels of the DIDO1
protein. This study demonstrates proof of concept in applying an antibody-basedmicroarray approach to iterativelymeasure the levels of
human proteins and relate these levels to human genome variation and other genomic data sets. Our results suggest that protein-based
mechanisms might functionally buffer genetic alterations that influence mRNA expression levels and that pQTLs might contribute
phenotypic diversity to a human population independently of influences on mRNA expression.Introduction
Our ability to sequence genomes at an ever-increasing rate
has resulted in the identification of many new common
and rare genetic variants across human populations.1–3
Much effort has been devoted to identifying relationships
between genetic variation and complex human pheno-
types, including susceptibility to disease and adverse
drug response.4–6 Developing a mechanistic biological
understanding of such statistical associations represents a
major ongoing challenge in human genomics.
Expression quantitative trait locus (eQTL) mapping has
been used to identify gene targets and mechanisms that
link genome variation with complex phenotypic traits.7–9
A fundamental assumption made in such studies is that
genome variants associated with mRNA expression varia-
tion will also be associated with protein-level variation
that impacts a trait. Although the influence of genetic vari-
ation on mRNA levels may extend to protein levels, many
posttranscriptionalmechanisms, suchasmRNAtranslation
efficiency, protein stability and function, and posttransla-
tional modification, can buffer changes in mRNA expres-
sion. Moreover, these same mechanisms can introduce
changes in protein levels under conditions of invariant
mRNA expression. Such protein-centric mechanisms can1Institute for Genomics and Systems Biology, University of Chicago, Chicago
University of Chicago, Chicago, IL 60637, USA; 3Ben May Department for Can
of Medicine, University of Chicago, Chicago, IL 60637, USA; 5Department of
delphia, PA 19104, USA; 6Department of Human Genetics, University of Chi
Pharmacogenomics, University of Chicago, Chicago, IL 60637, USA
8Present address: Veterinary Medical Research and Development, 425 Palouse
*Correspondence: edolan@medicine.bsd.uchicago.edu (M.E.D.), richardbjones
http://dx.doi.org/10.1016/j.ajhg.2014.07.005. 2014 The Authors
This is an open access article under the CC BY license (http://creativecommon
194 The American Journal of Human Genetics 95, 194–208, August 7bedecipheredonly bymeasuring genetic-,mRNA-, andpro-
tein-level variation among a population of individuals.
Indeed, previous examinations of genetic influences on
protein-level variation have observed markedly nonover-
lapping loci regulating protein and transcript levels.10–12
Unfortunately, we have been unable to globally compare
mRNA and protein levels with genetic variation across
human populations primarily because of the nonoverlap-
ping gene sets typically collected with current mRNA and
protein analysis platforms. Although mass spectrometers
(MSs) and MS-based protein analysis methods continue to
improve and can quantify thousands of proteins per sam-
ple, they currently lack the sensitivity required to consis-
tently observemore than a fraction of thehumanproteome
without depleting highly abundant proteins.13 A major
problem for most population-level proteome-by-transcrip-
tome comparisons employing mass spectrometry is the
biased sampling of proteins across samples; typically, sub-
sets of proteins are detected andquantified in some samples
but undetected in others.10,11,14,15 This biased detection
issue coupled with bias to observe and quantify the most
abundant proteins within a sample16 results in reduced
power to assess the relative contributions of genome influ-
ences to the proteome. To better relate genomes to tran-
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and applied complementary antibody-based ‘‘protein-
omic’’ approaches to more reproducibly quantify targeted
sets of protein families across individuals provided the
availability of validated antibodies directed against the pro-
teins of interest.17 We previously coined the term protein-
omic to refer to studies that collect information on targeted
subsets of functionally related proteins, by contrast to pro-
teomic that refers to larger, more random sampling-based
analyses of the proteome, typically by mass spectrometry.
The first such large-scale protein-omic study in humans
quantified 42 proteins from blood fractions of individuals
from the inCHIANTI study using 20 commercially avail-
able protein analysis assays with varying sensitivities and
precisions.12 Eight cis and one trans pQTL were identified.
More recently, an aptamer-based approach was used to
quantify proteins in human plasma, resulting in the iden-
tification of cis-linked associations for 60 proteins.18 2D
gels and mass spectrometry were used to quantify hun-
dreds of the most highly abundant proteins across
HapMap cell lines and the Northern Sweden Population
Health Study cohort to identify cis but not trans genetic
associations.14,19,20 In this report, we developed a stan-
dardized protocol using micro-western arrays (MWAs)21
and reverse phase protein arrays (RPPAs) to quantify 441
proteins across 68 unrelated Yoruba (YRI) lymphoblastoid
cell lines (LCLs) with a panel of antibodies directed at
nearly all human transcription factors (TFs) and many dis-
ease-related cell-signaling proteins. We then identified
pQTLs and compared the genetic architecture underlying
mRNA and protein level variation. Our study systemati-
cally examined the relationships between pQTLs and
eQTLs, replicated the initial discoveries of pQTL associa-
tions, and for the first time functionally validated a trans
pQTL. Our results indicate that novel mechanisms under-
lying complex disease risk loci are likely to be revealed
through further systems-level protein-omic analyses of
cells and tissues across human populations.Material and Methods
Cell Lines
Lymphoblastoid cell lines (LCLs, n ¼ 68) derived from unrelated
Yoruba individuals in Ibadan, Nigeria, were obtained from Coriell
Institute for Medical Research. They have been genotyped at more
than 3.1 million SNPs22 and had their RNA quantified by expres-
sion arrays,23,24 exon arrays,25 and RNA-seq.26 LCLs were cultured
in RPMI 1640 (Mediatech)/20 mM l-glutamine (Mediatech) plus
20% FBS (HyClone Laboratories) for the initial passage and then
passaged every 48 hr with LCL medium containing 15% FBS.
Cell suspensions were transferred to 25 cm2 flasks and incubated
at 37C in a humidified 5%CO2 atmosphere. Cell lines weremain-
tained at a concentration of 3.5–4.0 3 105 cells/ml and harvested
after the fourth passage, if viability wasR85%.Protein Isolation
Three pellets from each of 68 YRI LCLs were independently
thawed, cultured, split, pelleted, and stored at 80C. PelletsThe Amerfrom each independent freeze-thaw were resuspended in 1.0 ml
of 1.5% SDS lysis buffer (240 mM Tris-acetate, 1.5% w/v SDS,
0.5% w/v glycerol, 5 mM EDTA) containing 50 mM DTT, protease
(1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin), and
phosphatase inhibitors (1 mM sodium orthovanadate, 10 mM
b-glycerophosphate). To ensure complete protein denaturation,
samples were boiled for 10 min, sonicated for 10 min (alternating
30 s on, 30 s off) with a Bioruptor (Diagenode), and concentrated
to 5–10 mg/ml in a 96-well microconcentration device with a
10 kDa molecular weight cutoff (Millipore).Antibody Screening
The first antibody set comprised 296 previously validated anti-
bodies directed against 200 unique cell signaling proteins.21,27,28
The second antibody set represented a completely uncharacterized
set of 4,070 antibodies directed against 1,848 unique TFs. Three
biological replicates for each of 11–12 individuals were pooled
together into 6 pools for screening of these 4,366 rabbit polyclonal
antibodies at a 1:1,000 dilution. Printing, gel fabrication, horizon-
tal semidry electrophoresis, transfer, blotting, and scanning were
performed as in Ciaccio et al.,21 permitting 96 antibodies to be
screened over six pooled lysates per MWA. Antibodies were probed
in the 800 channel using goat anti-rabbit IR800-conjugated sec-
ondary antibodies (1:5,000) (Invitrogen). A validated mouse
monoclonal antibody to b-actin (1:1,500) (Cell Signaling 3700)
was included on each blot as a printing control and was measured
using a goat anti-mouse Alexa Fluor 680-conjugated secondary
antibody (1:7,500) (Invitrogen) in the 700 channel. Fluorescence
was quantified using LI-COR Odyssey software (v.3.0) by drawing
features around the appropriately sized bands for each sample
with a fluorescent protein marker (LI-COR 928-40000) acting as
a standard for molecular weight. The raw integrated intensities
of each feature were background subtracted using the median of
the three pixels surrounding the feature as an estimate of local
background, the maximum number of pixels permitted by the
LI-COR Odyssey image analysis software to be used for local
background estimation. These corrected integrated intensities
were used to calculate the average background-corrected inte-
grated intensities of replicate spots. Antibodies that displayed a
single predominant band of the predicted size of the targeted pro-
tein isoform of interest that accounted for >75% of the entire
signal of the lane with a signal-to-noise ratio R3 were selected
for subsequent population-level quantification by RPPAs; anti-
bodies that displayed at least one band of the predicted size of
the targeted protein isoform of interest with a signal-to-noise ratio
R3 but also additional bands were selected for subsequent popu-
lation-level quantification by MWAs. Antibodies that passed this
screen are listed in Table S2 available online.RPPA Protein Level Quantification
Four technical replicates of each of three biological replicates of
all 68 individuals were spotted using a noncontact piezoelectric
microarrayer (GeSiM Nanoplotter 2.1E) onto nitrocellulose mem-
branes (BioRad). Serial dilutions of each of the six pooled lysates
used for the original antibody screen and lysates from an A431 cer-
vical carcinoma cell line (which was used as a positive control for
antibodies) were also printed for each array to ensure linearity of
antibody signal. Features with a background-subtracted integrated
intensity<0 or signal-to-noise ratio<3 (z test p > 0.05) were iden-
tified in each array and excluded from further analysis. The distri-
butions of background-corrected integrated intensities for allican Journal of Human Genetics 95, 194–208, August 7, 2014 195
features on each array were first log2-quantile normalized using
the limma29 package in R to correct for overall antibody hybridiza-
tion efficiency differences in the signal. The relative level of a
given protein for a sample was then quantified using the linear
model yjp ~mjp þ lj þ e (Equation 1), where mjp is the log-quan-
tile-normalized, background-corrected integrated intensity of
sample j on array p, and lj is the effect due to sample j across all
arrays in a print (due to differing amounts of total protein spotted
on the array for each sample), estimated by medianj (mjp). Notably,
we performed an extension of median loading normalization30
and did not normalize to housekeeping proteins such as b-actin
or a-tubulin as is typically performed with traditional western
blotting to correct for sample load, because interindividual b-actin
mRNA levels varied by two orders of magnitude in the RNA-seq
data. Odyssey output text files were parsed in Python and quanti-
fied and normalized in R.MWA Protein Level Quantification
Three technical replicates of each of the three biological replicates
of all 68 individuals were spotted as above onto polyacrylamide
gels. Gel fabrication, horizontal semidry electrophoresis, transfer,
and scanning were performed as in Ciaccio et al.21 with the excep-
tion of separating each blot into four quadrants rather than using a
96-well gasket. Thismethod allowed for 68 samples to be quantified
with a single antibody in triplicate from each of four quadrants.
Feature extraction and data normalization were performed the
same as with RPPAs. For antibodies that produced multiple signifi-
cant bands (signal-to-noise ratio > 3), all isoforms were quantified
and their relative molecular weights recorded. The level of a given
protein for an individual was quantified using the above linear
model (Equation 1) with the addition of a batch term (b) to correct
for global intensity distribution differences across multiple MWAs
for the same antibody. We averagedmeasurements across replicates
within platforms for the same antibody across the entire popula-
tion. For replicates across platforms, we selected the platform that
yielded the highest median background-corrected integrated inten-
sity. To reduce the inflated effect of technical noise because of low
antibody signals and provide more accurate interindividual protein
level measurements, antibodies in the bottom deciles of median
background-corrected integrated intensities or in the top deciles
of technical coefficients of variation for either platform were
flagged and eliminated from further analyses.Quality Metrics of the Protein Measurements
To correct for differences in the total amount of protein deposited
for each sample for each array, we estimated a sample load effect
by regressing out the median protein measurement for each sam-
ple. This measurement was highly correlated with the first prin-
cipal component of the protein data, as the overall concentration
of each sample was directly related to the amount of each protein
(R2> 0.95). To assess the quality of our protein data, we plotted the
coefficients of variation for each antibody quantified versus the
median signal-to-noise ratios and background-corrected inte-
grated intensities (Figure S1). Similar to the effect observed with
expressionmicroarrays, we observed relatively high technical vari-
ation for antibodies of low fluorescence signal and a trend toward
decreased variation as fluorescence signal began to exceed the
noise floor of our proteomic platform. Therefore, we removed pro-
tein measurements in the bottom quartiles of signal-to-noise ratio
and background-corrected integrated intensity and the top quar-
tile of coefficient of variation. The application of these filters196 The American Journal of Human Genetics 95, 194–208, August 7reduced the effect of technical variation on our later inferences.
We observed a median s of 0.47 between interindividual protein
levels quantified by RPPAs andMWAs from seven antibodies quan-
tified across both platforms (example shown in Figure S2).
Comparatively, the median s between expression arrays and
RNA-seq for any given transcript across the same population of
YRI individuals has been shown to be approximately 0.12.26
To validate that the antibodies generated against epitopes
within each protein were targeting the protein of interest, we per-
formed two analyses. First, for the 57 pairs of antibodies directed at
different epitopes for the same protein that passed our screen, we
tested for correlated measurements between interindividual pro-
tein levels measured by both antibodies. We observed that 44 of
the 57 had correlated measurements (r> 0). Discordance between
multiple antibodies to the same protein could be because of tech-
nical variation or differential isoform levels, because each epitope
is directed to a unique region of each protein. Second, approxi-
mately 50 amino acids surrounding known antibody epitopes
(because exact epitope information was proprietary) were remap-
ped to the human genome (UCSC Genome Browser build hg18)
using BLAT31 and epitopes that contained at least one nonsynon-
ymous SNP from dbSNP (release 132)32 or matched multiple re-
gions in the genome with at least 95% identity were flagged but
retained, because the proprietary nature of epitope disclosure pre-
vented us from knowing which ~5–8 amino acid fragment of the
50 amino acids was used to create the antibody.Gene Expression Data
Expression array data for 53 individuals included in our study
from Illumina’s human whole-genome expression arrays (WG-6
v.1) from Stranger et al.24 were downloaded fromGene Expression
Omnibus (GSE6536). Probes were remapped to the human
genome (UCSC Genome Browser build hg18) using BLAT31 and
probes that mapped to a single location with less than 100%
sequence identity or mapped to multiple locations with up to
two mismatches were discarded. We then excluded probes that
contained at least one SNP in dbSNP (release 132)32 or our
imputed common SNP genotypes for our cohort or overlapped
copy-number variants in the YRI population.33
Exon array data for 52 individuals overlapping our study from
the Affymetrix GeneChip Human Exon 1.0 ST Array platform
from Zhang et al.34 were downloaded from Gene Expression
Omnibus (GSE9703). Probes were mapped to UCSC Genome
Browser build hg18 and probes containing at least one SNP were
removed from probe set signal intensity files. Gene-level expres-
sion of transcript clusters was summarized with RMA35 and aver-
aged within unique Ensembl gene annotations.
RNA-sequencing data were obtained for all individuals in our
study from Pickrell et al.26 Gene expression values were calculated
as the number of GC-corrected reads mapping to a gene in an
individual, divided by the length of the gene in kilobases and
the number of mapped reads across all lanes for that individual
in millions (RPKM).Cellular Covariates and Hidden Confounders
We quantified the EBV copy number in all LCLs. EBV copy
number was assessed with a Taqman Gene Expression Assay
(Pa03453399_s1). Intrinsic growth rates for each cell line from
Im et al.36 and baseline ATP and mitochondrial DNA levels from
Choy et al.37 were also included in the analyses. To identify poten-
tial additional unobserved confounders, we applied surrogate, 2014
variable analysis (SVA) to the matrix of 68 3 3 protein level mea-
surements after including the effects of known nongenetic con-
founders to identify 16 additional significant surrogate variables.
Covariate Modeling
For each protein measurement, we constructed a linear mixed
effects model y ~p þ E þ M þ A þ G þ S þ P þ TjI þ SVi..n þ e, in
which p is the array- and sample-load-normalized integrated in-
tensity for all biological replicates in the population, E is the fixed
effect of individual EBV copy number,M is the fixed effect of indi-
vidual mitochondrial DNA copy number, A is the fixed effect of in-
dividual baseline ATP levels, G is the fixed effect of individual
intrinsic growth rate, S is the fixed effect of individual sex, P is
the fixed effect of individual phase, TjI is the random thaw effect
per individual, SVi..n are the effects of amatrix of 16 significant sur-
rogate variables, and e is the residual error. The model was fitted to
each protein by residualmaximum likelihood using the lmer func-
tion in the R package lme4 (v 0.999999-0). Fixed effect p values
for covariates were estimated using the pamer.fnc function in
the LMERConvenienceFunctions package (v.1.6.8.3). The signifi-
cances of covariate effects were assessed by estimating false discov-
ery rates using Storey’s q value method.
Genotype Data
HapMap genotypes were obtained from the 1000 Genomes June
2011 phase I low-pass whole-genome SNP genotype release and
transformed to UCSC Genome Browser (hg18) coordinates.
Missing values were imputed by BIMBAM (v.1.0) using the default
parameters to derive mean imputed genotypes. SNVs with MAF <
0.05 and SNVs with significant deviation from Hardy-Weinberg
equilibrium (Fischer’s exact test, p < 0.001) were excluded,
reducing the set to 9,345,571 SNPs and indels for association
analyses.
Association Analyses
For each protein and transcript trait, interindividual levels were in-
verse normal transformed and tested for association with all
markers genome-wide. Association testing was performed by
linear regression implemented in Python and R using custom
scripts. For each trait, we selected the most significantly associated
SNV within each recombination window, defined by splitting the
genome into 25,307 blocks flanked by>10 cM/Mb recombination
rates estimated fromHapMap.22 All SNV-protein associations with
p< 104 for proteins with more than one biological replicate were
validated with the linear mixed-effects model y ~p þ G þ TjI þ e
with a fixed genotype variable, G.
Significant Associations
We performed genome-wide permutations to assess the signifi-
cance of the association results. We permuted the 468 protein
values for each biological replicate for all individuals, performed
genome-wide association on the permuted and normalized phe-
notypes, and repeated this procedure for three replicates, selecting
each time the best signal per phenotype. Permuted SNV-protein
associations with p < 104 were tested with a linear mixed-effects
model as above. False discovery rate (FDR) was calculated as the
fraction of significant hits in the permuted versus the observed
data at a given p value threshold. FDR was calculated separately
for cis and trans pQTLs. Results are presented at FDRs of 5% and
20%, meaning that an estimated 5% and 20% of the pQTLs
correspond to false positives, respectively. We chose to perform as-The Amersociation analyses on protein and mRNA measurements without
covariate and SV correction because correction for known covari-
ates, SVs, or both did not improve RNA-protein correlations (p >
0.05, Wilcoxon rank sum test). We observed fewer cis and trans
pQTLs at an FDR< 0.20 after correction (suggesting that we might
be discarding some fraction of genetic variation associated with
protein level variation, as has been previously demonstrated in
methods to optimize cis eQTL discovery by iteratively removing
PCs to maximize the number of eQTLs discovered26,38) and to be
consistent with all previous pQTL studies to date10–12,14,19,20 to
allow more direct comparison of our results. The association ana-
lyses and FDR calculations were performed for all autosomal surro-
gate variables (n ¼ 16), protein values, and genes in the mRNA
expression data sets.
Enrichment of Specific Types of SNVs in pQTLs
and eQTLs
The annotation of all SNVs was performed using SeattleSNPAnno-
tation 129. For each unique annotation (‘‘coding-synonymous,’’
‘‘intergenic,’’ ‘‘intron,’’ ‘‘missense,’’ ‘‘near-gene-3,’’ ‘‘near-gene-5,’’
‘‘nonsense,’’ ‘‘splice-3,’’ ‘‘splice-5,’’ ‘‘utr-3,’’ and ‘‘utr-5’’), we used
a Fisher exact test to test the null hypothesis that the fraction of
that annotation type in either recombination-block-filtered eQTLs
or pQTLs for overlapping genemodels at p< 104 was equal to the
fraction in all annotated SNVs.
Genome-wide Association Study Results and
Enrichment Analyses
All SNPs published by 02/01/2012 were downloaded from the
catalog of GWASs maintained by the NHGRI and filtered for
5,570 common variants (MAF > 5%) in the YRI samples exam-
ined. For overlap with eQTLs and pQTLs, we considered all
SNPs in linkage disequilibrium (LD) (R2 > 80%) with the com-
plex-trait-associated SNPs and filtered for common variants
(MAF > 5%) in the YRI samples examined. To determine the
enrichment for SNPs associated with each complex trait to be
eQTLs or pQTLs, we focused on only the 7,222 primary-trait-asso-
ciated SNPs before LD imputation to correct for LD-driven infla-
tion of enrichment results. We then generated 1,000 randomized
SNP sets each of size 7,222 and matched on MAF distribution by
proportions in discrete 5% MAF bins. For each set, we determined
the number of eQTLs and pQTLs at p < 104 for traits with at
least three observed expression QTL overlaps and derived an
empirical p value by comparing the proportion of random simu-
lations in which the number of random overlaps exceeded the
observed overlap.
siRNA Knockdown
LCLs were seeded at a density of 550,000 cells/ml 24 hr before nu-
cleofection. Amaxa’s Cell Line 96-well Nucleofector Kit SF (Lonza)
was used to perform the transfection. Cells were centrifuged at
90 3 g for 10 min at room temperature and resuspended at a con-
centration of 1,000,000 cells in 20 ml of SF/supplement solution
(included in SF Kit Lonza Catalog #V4SC2096) and 2 mMfinal con-
centration of AllStars negative Control siRNA labeled with Alexa
Fluor 488 (QIAGEN) or a pool of siRNA (QIAGEN) (Table S1).
The cells were nucleofected using Amaxa’s DN-100 program. Cells
were allowed to rest for 10 min before the addition of prewarmed
(in 37C water bath for a minimum of 20 min) RPMI media and
then another 5 min after the addition of warm RPMI media. Cells
were then plated for protein harvest. Cells were harvested at 24ican Journal of Human Genetics 95, 194–208, August 7, 2014 197
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Figure 1. Schematic Representation of the Experimental Design
(A) Three biological replicates from each of 68 YRI lymphoblastoid cell lines were passaged, pelleted, and lysed.
(B) These lysates were aggregated into six pools for screening 4,366 polyclonal antibodies at a 1:1,000 dilution.
(C and D) Antibodies that produced only a single (C) or at least one (D) predominant band the size of the target protein with a signal-to-
noise ratioR3 were subsequently scaled up for population-level quantification by RPPAs and MWAs, respectively.
(E) Sample load and batch effects were then regressed out to derive a final matrix of 68 individuals by 441 protein levels.
(F) Residuals were inverse normal transformed and associated with 9,345,571 SNVs genome-wide to identify pQTLs. Triangles, circles,
and diamonds correspond to biological replicates.
(G) A random subset of antibodies was validated by siRNA knockdown and pQTLs were tested for replication in an independent cohort
of 17 unrelated YRI LCLs.and 48 hr postnucleofection for protein measurement by MWAs.
Protein levels were quantitated as above with three technical
replicates per individual per time point and normalized within
an individual across time points to the relative b-actin protein
levels. Percentage knockdown was then calculated by dividing
the relative targeted protein levels in the targeted siRNA sample
by those in the scrambled siRNA control sample for each time
point. A knockdown was declared significant if protein levels
were reduced after knockdown by greater than two times the per-
centage standard error (p < 0.05).Results
Study Design and Protein Quantification
To characterize the genetic architecture of a targeted subset
of proteins in humans, we measured protein levels from
three independently cultured replicates (hereafter termed
biological replicates) of 68 HapMap YRI LCLs for which
genotypes, mRNA expression,24,26,34 and pharmacologic
data39 were available. A common problem encountered
with contemporary affinity-based protein-omic studies17
is the lack ofwell-validated antibodies at economical prices.
We therefore took a two-pronged approach tomaximizeour
ability to collect high-quality protein data and to compre-
hensively collect data on poorly characterized and lowly198 The American Journal of Human Genetics 95, 194–208, August 7expressed transcription factors (TFs). Our antibody set
comprised 4,366 antibodies directed against 1,848 unique
TFs and 200 unique cell signaling proteins. We screened
these antibodies against six pools of lysates comprising 68
YRI individuals (Figures 1 and S3; Table S2). A total of 207
antibodies produced a single predominant signal at the pre-
dicted molecular weight and were subsequently used to
quantify protein levels via the RPPA approach (representa-
tive array shown in Figure S4 and Table S3). Because RPPAs
lack the ability ofMWAs to electrophoretically separate pro-
teins, sample throughput and image analysis are more
rapid. However, much higher selectivity antibodies are
required for RPPAs than for MWAs to obtain meaningful
data.40 A total of 234 antibodies that produced signals in
addition to those at the predicted molecular weight were
measuredat thepopulation level viaMWAs (Figure S5; Table
S4). This approach ultimately allowed us to quantify pro-
tein levels from 441 antibodies (341 TF and 100 signaling)
directed at 391 unique protein isoforms (Table S5) across
68 LCLs cultured on three independent occasions.
We established the quantitative accuracy of our
approach by several independent methods. First, to
address sources of technical variation in our measure-
ments, we established methods to normalize and filter
the protein data as described in the Methods. Second, we, 2014
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Figure 2. Relationship between Tran-
script and Protein Levels
(A) Correlation between Illumina array
and RNA-seq expression measurements
within individuals. Log2-transformed
expression estimates derived from the
array are plotted with a smoothed density
against log2-transformed RPKMs derived
from RNA-seq. Explicit circles denote
genes with corresponding protein-level
quantifications.
(B) Boxplots of Spearman correlation
coefficients between RNA-sequencing, Af-
fymetrix exon array probe sets, Illumina
expression array probe sets, and antibodies
targeted to the same gene for all 68 indi-
viduals. The boxplots are labeled as follows: (a) RNA-seq versus exon arrays, (b) exon arrays versus expression arrays, (c) RNA-seq versus
expression arrays, (d) protein versus expression arrays, (e) protein versus exon arrays, and (f) protein versus RNA-seq.observed that 13 pairs of antibodies targeting different epi-
topes for the same proteins resulted in significantly corre-
lated measurements for their intended targets across all
individuals (p < 0.05) (Figure S6). Third, we observed
a strong preservation of interindividual rank order for
the same protein quantified by both RPPAs and MWAs
(example illustrated in Figure S2). Fourth, we verified that
the antibodies faithfully reported on the levels of their in-
tended targets by performing siRNA knockdown of 18 pro-
teins, 15 of which were randomly selected and 3 of which
were pQTL targets. Of the 18, 17 exhibited a significant
reduction in protein levels relative to a scrambled control
in at least one YRI LCL at one time point (Table S6).
Low Preservation of Rank Order between mRNA and
Protein Levels across All Individuals
We first compared the correlations between mRNA expres-
sion levelswithin individualsmeasured by three expression
platforms: Affymetrix exon arrays,25 Illumina expression
arrays,24 and RNA-sequencing (RNA-seq).26 We observed a
strong correlation between these independent measures
of transcript abundance for all genes (Figure 2A; RNA-seq
versus Illumina expression array, median r ¼ 0.67; RNA-
seq versus Affymetrix exon array,median r¼ 0.82; Illumina
expression array versus Affymetrix exon array, median r ¼
0.62). These observations support previous reports that
have demonstrated similarly highly correlated mRNA
expression measurements between RNA-seq and expres-
sion array technologies whenmeasuringmRNA expression
from a single individual (r ¼ 0.60–0.77).
However, for expression QTL analysis, the more relevant
comparison is how well expression levels correlate for each
gene measured across individuals. We examined the pres-
ervation of rank order between 173 overlapping gene-level
protein and mRNA measurements across the 52 individ-
uals that were examined in each study (Figure 2). Notably,
the correlation of interindividual mRNA expression mea-
surements was low across mRNA expression platforms
and laboratories (median r ¼ 0.09–0.17), consistent with
results from a previous eQTL analysis on this cohort using
all genes (median r ¼ 0.12).26 The correlation betweenThe AmermRNA levels was significantly higher between microarray
platforms (median r ¼ 0.17) than between microarrays
and RNA-seq (median r¼ 0.10, p¼ 2.803 104, Wilcoxon
rank sum test), indicating that either biological or platform
variance contributed substantial variability to previous
mRNA expression studies. Similarly to previous observa-
tions in yeast and mice,10,11,15 little correlation was
observed between transcript and protein levels within
genes, across individuals (exon array median r ¼ 0.03,
expression array median r ¼ 0.01, RNA-seq median r ¼
0.02) (Figure 2B). Although global mRNA and protein
levels were not strongly correlated across individuals,
they were enriched to be correlated with 12% of genes dis-
playing significant preservation of interindividual rank
order between mRNA and protein levels, even in the pres-
ence of biological variation associated with the propaga-
tion of cells across different laboratories.
Several cellular characteristics including intrinsic growth
rate, ATP levels, and EBV copy number have previously
been shown to associate with gene expression levels and
cellular phenotypes measured in LCLs.37,41,42 mRNA
expression data sets have previously been adjusted for
these cellular covariates to increase the ability to observe
relationships between genotypes and mRNA expression
levels.8,26,37 We surmised that these cellular variables
might also be related to protein levels. We therefore tested
for association between interindividual variation in these
variables andwith protein levels.We identified 197 protein
variants that were nominally associated with at least one of
six variables (Table S7). At an FDR of 5%, we found that 36
proteins were associated with intrinsic growth rate,35 28
proteins were associated with baseline ATP levels, and
21 proteins were associated with EBV copy number.
Levels of phospho-S6 ribosomal protein (RPS6) and struc-
tural maintenance of chromosomes protein (SMC1A)
were negatively correlated with cell growth (R ¼ 0.33,
p ¼ 1.86 3 106 and R ¼ 0.19, p ¼ 2.62 3 104, respec-
tively). Notably, we found that b-actin and a-tubulin pro-
tein levels were positively correlated with intrinsic growth
rate (R ¼ 0.12, p ¼ 1.36 3 105 and R ¼ 0.02, p ¼ 0.04,
respectively), suggesting that their use in total proteinican Journal of Human Genetics 95, 194–208, August 7, 2014 199
Table 1. Summary of Results for Association Analyses of Protein
Levels
SNP Protein Type p Value R
rs60664312 DIDO1 trans 5.55 3 1017 0.65
chr10.18096250 ZNF529 trans 4.21 3 1011 0.45
rs751473 p-Raf(S338) trans 8.91 3 1011 0.45
rs7232517 ZNF645 trans 9.94 3 1011 0.44
rs72918427 ZNF414 trans 1.05 3 1010 0.44
rs145614393 ZMYND11 trans 2.80 3 1010 0.58
rs4691394 STAT3B trans 5.66 3 1010 0.42
rs17020269 RUNX1 trans 6.72 3 1010 0.52
rs141517138 OVOL1 trans 7.31 3 1010 0.50
rs2016050 p-PDK1(S241) trans 7.44 3 1010 0.44
rs3893175 EP300 trans 7.85 3 1010 0.50
rs11663180 GATA4 trans 1.16 3 109 0.58
rs7331659 p-GAB1(Y659) trans 1.18 3 109 0.42
rs16911722 TFAP2 trans 1.77 3 109 0.45
rs4490893 IRF4 trans 2.28 3 109 0.41
rs16870965 TFAP2 cis 2.72 3 108 0.41
rs1638320 MED16 cis 1.22 3 107 0.44
rs10864374 ENO1 cis 1.22 3 107 0.40
rs7256500 ZNF266.75-100 cis 1.68 3 107 0.37load normalization as housekeeping proteins, rather than
the median sample load normalization we performed,
would have resulted in an erroneous adjustment for
intrinsic growth rate differences between cell lines.
Nominally associating with 21% of protein-level and
25% of RNA-seq-derived mRNA-level measurements, in-
trinsic growth rate was correlated with the highest number
of mRNA and protein levels (Table S8). Indeed, of the 18
significant surrogate variables (SV) identified in the protein
data set, the first SV was significantly associated with
intrinsic growth rate (p ¼ 0.03) and EBV copy number
(p ¼ 0.05), and the third SV was associated with intrinsic
growth rate (p¼ 7.03 104), underscoring the high degree
of association between global protein levels, intrinsic
growth rate, and EBV copy number in LCLs.
pQTL Mapping and Replication in an Independent
Cohort of LCLs
We performed global pQTL mapping by testing for associa-
tion between the 441 protein level measurements and
genotypes at 9,345,571 single-nucleotide variants (SNVs).
At an FDR < 0.20, we identified 12 cis pQTLs (here defined
as within 1 Mb upstream of the transcription start site
[TSS] to 1 Mb downstream of the transcription end site
[TES] of the RefSeq genemodel) and 160 trans pQTLs (corre-
sponding to p< 3.263 106 for cis and p< 3.423 108 for
trans) (Table S9). Themost significant cis and trans pQTLs at
an FDR < 0.05 corresponded to 18 unique RefSeq gene200 The American Journal of Human Genetics 95, 194–208, August 7models (Table 1). This observationof largernumbers of trans
than cis pQTLs corroborates similar observations from pre-
vious pQTL studies in yeast11 and mice.15 We constructed
Circos plots to visually depict significant associations be-
tweenSNVs, protein levels (Figure3), andmRNAexpression
levels (Figure S7). The 12 most significant pQTLs as well as
the SNP associated with the most protein levels are illus-
trated in Figure 3; similarly, the ten most significant eQTLs
aswell as the SNPassociatedwith themostmRNA transcript
levels are shown in Figure S7. For example, rs60343174 was
significantly associated with the relative levels of eight pro-
teins, including OVOL1, ZNF414, and RUNX1 (Figure 3A).
To further validate the pQTL associations, we randomly
selected 20 proteins for quantification in three biological
replicates of a separate, unrelated cohort of 17 YRI LCLs
from Coriell and tested for replication of pQTLs for all as-
sociations discovered at p < 104 (Table S10). Of the eight
pQTLs (FDR of 0.20) that were associated with proteins
quantified in our replication cohort, seven had consistent
effect directions, and for two, the replications were
also nominally significant (rs145614393 and ZMYND11;
rs60664312 and DIDO1). The rs60664312-DIDO1 associa-
tion was the largest effect size pQTL in the discovery
cohort, whereas the rs145614393-ZMYND11 association
was of moderate effect size (Table S10). None of the 30
pQTL SNVs identified at an FDR < 0.05 was also signifi-
cantly associated with cellular covariates, suggesting that
cellular covariates did not confound pQTL identification.
Additionally, we observed more pQTLs before regressing
out known covariates and/or unknown confounding
effects as estimated by surrogate variable analysis. We
therefore chose to perform all further analyses using the
unadjusted protein values, identical in approach to all pre-
vious pQTL studies to date.10–12,14,19,20 Although no RNA-
seq eQTLs identified at an FDR < 0.05 correlated at simi-
larly stringent p values in our protein data as pQTLs, the
most significant cis eQTL identified at an FDR < 0.05 was
also a nominally significant pQTL: an association between
variation at rs2116843, an intergenic SNP approximately
20 kb upstream of the transcription start site (TSS) of
ZNF266 (MIM 604751), and variation in ZNF266 expres-
sion at themRNA (p¼ 1.543 109, b¼0.65) and protein
level (p ¼ 0.003, b ¼ 0.21) (Figure 3B). This observation
provided an example of a genetic variant that associated
with both the mRNA and protein level, as would be ex-
pected if the genetic variant causally influenced mRNA
and subsequently influenced protein level variation. We
also observed another, more significant cis pQTL for
ZNF266, rs7256500 (p ¼ 1.68 3 107, b ¼ 0.37), which is
an intronic SNP located approximately 0.8 Mb upstream
of the TSS of ZNF266 within MYO1F (MIM 601480) that
was not in LD with rs2116843 (r2 ¼ 0.04). This pQTL was
not significantly associated with mRNA expression levels,
although the effect trend was in the same direction (p ¼
0.15, b ¼ 0.18). Additionally, rs6695435, an intergenic
variant located 4 kb upstream of the TSS of TBX19 (MIM
604614), had a subtle but not significant association with, 2014
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Figure 3. Genetic Variants Affecting Protein Levels Globally and in cis
(A) Circos plot for the pQTL association results. The rims, in order from outside inward, are (1) a karyotype defining chromosome co-
ordinates, (2) a Manhattan plot of the –log10(P) for each pQTL identified at p < 10
4 (for plotting clarity) with the red line designating
p ¼ 108, and (3) the top 12 (constrained due to space) significant pQTLs (p < 1010) and the top master regulatory pQTL SNV
rs60343174. The innermost network depicts spokes between pQTLs and their regulated genes, with dark blue spokes depicting the
top pQTL interactions (such as rs6834with DIDO1 protein levels) and light blue spokes depicting proteins associatedwith the topmaster
regulatory pQTL.
(B) RNA-seq and protein measurements (y axis) for each sample plotted by SNP genotype for a replicated cis eQTL for ZNF266.
Error bars represent 95% confidence intervals.
(C) RNA-seq and protein measurements for TBX19 versus SNP genotype for a representative cis pQTL.mRNA expression as measured by RNA-seq (p ¼ 0.28, b ¼
0.14) (Figure 3C), but a significant association with concor-
dant effect direction on TBX19 protein levels (p ¼ 5.17 3
106, b ¼ 0.33) and was one of the closest cis pQTLs to
the TSS of the gene model that we identified.
We observed significantly more trans associations
with protein levels than with mRNA levels (160 transThe AmerpQTLs for 78 unique proteins versus 0 trans eQTLs at an
FDR ¼ 0.20). The most significant pQTL identified was
the association between SNP rs60664312 and DIDO1 pro-
tein levels (p¼ 5.553 1017, b¼ 0.65). We observed an in-
tergenic indel on chromosome 6 (rs60343174) that was
associated with eight different protein levels at p < 104
and that was most significantly associated with LMX1Aican Journal of Human Genetics 95, 194–208, August 7, 2014 201
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Figure 4. Comparison of the Genetic Regulation of Transcript and Protein Levels
(A) Proportion of annotations other than ‘‘intron’’ and ‘‘intergenic’’ for all SNVs, eQTL SNVs, and pQTL SNVs.
(B and C) Log odds that an eQTL (B) or a pQTL (C) is a particular annotation type versus all SNVs in the study.
(D and E) cis-eQTL (D) and trans-eQTL (E) replication rate (y axis) is depicted as a function of the p value in transcriptome sequencing (x
axis) for Illumina expression array (green), Affymetrix exon array (blue), and protein data (purple). The black dashed lines denote the
number of eQTLs at each discovery p value. The gray dashed line denotes the null expectation of replication rate at p< 0.05 with concor-
dant effect direction.(p¼ 5.663 109, b¼ 0.51) (Figure 3A). Consistent with re-
sults from Wu et al.,14 we observed that measurements
of protein variation were not significantly influenced by
posttranslational modifications for the proteins for which
both pan- and phospho-specific validated antibodies were
available. However, three of the most significant trans
pQTLs were intergenic variants affecting the levels of a
phosphorylated isoform of three proteins but not their
overall abundances as inferred using pan-specific anti-
bodies (p > 0.05): rs7331659 and p-Gab1 (Y659),
rs751473 and p-Raf (S338), and rs2016050 and p-PDK1
(S241) (Figure 3A). This observation represents, to our
knowledge, the first evidence of genetic variants associated
with the phosphorylated version of a protein and repre-
sents a first step toward identifying common genetic vari-
ants associated not only with protein levels, but also with202 The American Journal of Human Genetics 95, 194–208, August 7their modification states, which often serve as proxies for
their activation states.
Comparison of Genetic Variants Associated with
mRNA and Protein Levels
Wenext examined the functional classifications, locations,
and reproducibility of genetic loci affecting protein abun-
dances. We compared the newly identified pQTL loci
with eQTL loci that we identified using RNA-seq expres-
sion for the 373 genes with overlapping protein and
mRNA measurements (Figure 4). We first compared the
relative proportions of annotations of eQTLs and pQTLs
versus all SNVs used in our study (Figure 4A; Table S11).
eQTLs were significantly enriched near the 50 and 30 ends
of genes and at the 50 UTR (p ¼ 6.63 3 109, p ¼ 1.49 3
103, and p ¼ 6.27 3 1013, respectively) and depleted in, 2014
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Figure 5. Identification and Validation
of a trans pQTL for DIDO1
(A–C) Protein discovery (A), replication
cohort (B), and transcriptome sequencing
expression (C) measurements (y axis) for
each sample plotted by SNP genotype for
a replicated trans pQTL for DIDO1.
(D) Regional association plot of the genic
region associated with DIDO1. The
–log10(p value) for SNVs in this region
(left y axis) and recombination rate (right
y axis) are depicted with respect to
genomic position (x axis) using Locus-
Zoom.45 SNVs in LD with the most associ-
ated SNP are plotted according to the color
scale.
(E) KARS protein levels versus genotype in
the replication cohort of 17 YRI LCLs.
(F) DIDO1 protein, but not mRNA, expres-
sion levels were significantly reduced 24 hr
after siRNA knockdown of KARS. Error bars
indicate the SEM of three technical repli-
cates for each condition.introns (p ¼ 1.42 3 103) (Figure 4B). This finding is
consistent with observations from previous global eQTL
studies that eQTLs tend to cluster near the TSSs of
genes24,26 and in exons relative to introns.43 pQTLs were
enriched near gene 30 ends (1.14 3 103), in 50 or 30
UTRs (p ¼ 0.03, p ¼ 0.03), in synonymous coding variants
(p ¼ 0.02), and notably, in missense variants (p ¼ 1.58 3
105) (Figure 4C). These observations indicated that ge-
netic variants associated with protein level variationmight
involve protein stability or miRNA-mediated regulation of
mRNA translational efficiency. We next examined the
reproducibility of eQTLs across platforms and at the pro-
tein level (defined as a nominal p< 0.05 with a concordant
effect direction) as a function of the p value of the discov-
ery association in RNA-seq. We observed that cis and trans
eQTLs discovered at p < 104 were more likely to replicate
across platforms and as pQTLs than expected by chanceThe American Journal of Human G(Figures 4D and 4E). All four of the
most significant cis eQTLs (p < 106)
replicated by both the Illumina
expression array and Affymetrix
exon array, and three were nominally
significant cis pQTLs. Two of these cis
eQTLs were located in adjacent
recombination blocks and associated
with ZNF266; indeed, despite being
split by an average 29 cM/Mb recom-
bination rate across the 20 kb gene
transcription region centered at
chr19: 9,348,911,22 these SNPs re-
mained in high LD (r2 ¼ 0.99). How-
ever, trans eQTLs failed to replicate
well across mRNA expression plat-
forms or between mRNA and protein
measurement platforms (Figure 4E).
This observation was consistent withpreviously reported examples demonstrating the difficulty
in replicating trans eQTLs.8,44 Only 1 of the 10 cis pQTLs
(rs7256500 and ZNF266) and 6 of the 49 trans pQTLs iden-
tified at an FDR < 0.20 replicated at the mRNA level, indi-
cating that few genetic variants that were strongly associ-
ated with protein levels were also associated with mRNA
expression (Figure S8). These observations suggested that
many of these genetic variants might affect protein levels
independently of their effect on transcript levels.
The Lysyl-tRNA Synthetase KARS Underlies a trans
pQTL for DIDO1
Above, we noted the identification of the SNP rs60664312
as a significant trans pQTL for Death Inducer-Obliterator 1
protein (DIDO1) (p ¼ 5.55 3 1017, Figure 5A) and subse-
quently validated the trans pQTL relationship for DIDO1
in a replication cohort (Figure 5B). This pQTL was not anenetics 95, 194–208, August 7, 2014 203
Table 2. Selected Overlap between pQTLs and GWAS SNPs
Trait SNP PMID Chr Protein p Value
Conduct disorder
(case status)
rs2184898 20585324 10 PRDM2 1.44 3 108
LDL cholesterol rs2738459 20864672 19 ZNF207 1.32 3 107
Metabolic
syndrome
(bivariate traits)
rs320 21386085 8 ZMYND11 4.88 3 107
Platelet
aggregation
rs1659838 20526338 10 ZMYND11 5.55 3 107
HIV-1 viral
setpoint
rs6997496 22174851 8 FAK 1.15 3 106
Leprosy rs10792430 22019778 11 OSR1 1.37 3 106
Primary biliary
cirrhosis
rs10792430 21399635 11 OSR1 1.37 3 106
Blood pressure rs17417407 21909110 10 TWIST1 1.39 3 106
Response to
interferon
beta therapy
rs9272105 21502966 6 SRC 1.44 3 106
Cytomegalovirus
antibody
response
rs931547 21993531 1 NCKAP1L 2.24 3 106
LDL cholesterol rs4971544 21059979 2 NKX3-2 2.33 3 106
Cytomegalovirus
antibody
response
rs211228 21993531 6 MYST4 2.80 3 106eQTL (p > 0.05, Figure 5C) based on previous mRNA
expression data. DIDO1 is involved in limb development
and the induction of apoptosis in mice.46 This pQTL exists
in a linkage disequilibrium (LD) block that contains the
genes ADAT1 (MIM 604230), KARS (MIM 601421), and
TERF2IP (MIM 605061) (Figure 5D) but was not described
as a cis eQTL for any of these genes in previous mRNA
expression studies (p > 0.05). However, rs60664312 is
located 4 kb upstream of the TSS of KARS and is in high
LD (r2 ¼ 0.87) with rs6834 (RefSeq accession number
NP_001123561.1; p.Thr623Ser, DIDO1 pQTL p ¼ 2.66 3
1015, b ¼ 0.63), a nonsynonymous variant for KARS
that would be predicted to influence the ability of the pro-
tein to be phosphorylated by a protein kinase. To examine
whether this variant was expected to be functionally sig-
nificant, we assessed Genomic Evolutionary Rate Profiling
(GERP),47 and Sorting Intolerant From Tolerant (SIFT)48
scores. GERP scores address nucleic acid sequence preserva-
tion during mammalian evolution. Scores >2 are consid-
ered ‘‘constrained’’ and are more indicative of a deleterious
polymorphism. SIFT scores attempt to predict whether an
amino acid substitution will affect protein function based
on the degree of conservation of amino acid residues in
sequence alignments derived from closely related se-
quences, with scores<0.05 being considered ‘‘deleterious.’’
RefSeq NP_001123561.1 (p.Thr623Ser) was predicted to be
extremely deleterious at the nucleic acid level (GERP score
¼ 5.82), despite being predicted to be well tolerated at the204 The American Journal of Human Genetics 95, 194–208, August 7protein function level (SIFT score ¼ 0.47). We next quanti-
fied KARS protein levels in a replication cohort and exam-
ined whether the SNP rs60664312 was a pQTL for KARS.
We observed a significant correlation with KARS protein
levels for both rs60664312 and rs6834 (p < 0.002 for
both comparisons) in the same effect direction as DIDO1
levels. The minor allele of rs6834 was associated with
higher DIDO1 and KARS protein abundances, respectively
(Figure 5E). To examine the causality of this relationship
between DIDO1 and KARS protein levels, we performed
siRNA-mediated knockdown of KARS and observed a
concomitant reduction in DIDO1 protein levels (p <
0.001) without effects on DIDO1 mRNA levels (p > 0.05)
as measured by qRT-PCR (Figure 5F). To address whether
knockdown of KARS would affect DIDO1 protein levels
specifically, we included ZNF569 as a negative control
and observed no reduction in ZNF569 protein levels after
KARS knockdown (Table S6). In summary, we identified a
SNP that appeared to influence DIDO1 protein levels
through the abundance and activity of KARS in a manner
that was independent of underlying KARS mRNA levels
and that was detectable only throughmeasurement of pro-
tein levels.Overlap of Complex Trait QTLs and pQTLs
Previous studies have demonstrated that common genetic
variants associated with complex traits significantly over-
lapped with eQTLs.7 Genetic risk factors have often been
assumed to influence complex traits through their effects
on mRNA expression. However, many posttranscriptional
mechanisms exist that could influence phenotypic vari-
ability through unique effects on protein abundances. To
explore this notion, we tested for overlap between pQTLs
identified here and complex-trait-associated SNPs in the
NHGRI GWAS catalog. Of the 7,222 SNPs associated with
612complexphenotypes anddiseases atp<108, 197over-
lapped with at least one pQTL at p < 104 (Table S12). We
identified several notable overlaps between pQTLs and
complex trait SNPs offering potential insights into the mo-
lecularmechanismsunderlying these phenotypes (Table 2).
For example, we identified an intergenic pQTL associated
with HOXB7 levels (rs991258) and two intergenic pQTLs
(rs731905 and rs9398038) for HOXB10 levels that overlap-
ped with SNPs that were previously found to be associated
with hip geometry,49 height,50 and primary tooth develop-
ment.51 HOXB7 and HOXB10 are members of the homeo-
box gene family and function to regionalize the embryo
along its major body axes.52Discussion
We utilized the MWA approach to screen more than 4,300
antibodies. From this screening effort we identified 441
antibodies against 391 unique proteins that we used for
subsequent quantification of relative protein levels within
a population of YRI LCLs. We performed comparative, 2014
analysis of the relationship between genetic variation and
between subsets of the transcriptome and proteome. We
replicated and functionally validated a significant trans
pQTL from our proteomic association analyses. Because
of the difficulties in comparison of existing large-scale
genomic and proteomic data sets, our study represents
one of the first to examine large-scale relationships be-
tween genome variation, mRNA expression, protein levels,
and protein modifications in human cells.
Our data complement studies that have been previously
undertaken in yeast and mice11,15 that indicated relatively
low interindividual correlations between mRNA and pro-
tein levels. Compared to studies conducted in yeast or
mice, we observed a slightly lower protein-transcript
concordance, but still approximately zero (median r ¼
0.02 for humans versus 0.07 for yeast). This lack of correla-
tion between mRNA and protein levels could partially be
because of technical variation, particularly limitations in
accurately quantifying lowly expressed mRNA transcripts
or protein abundances. However, the comparative analysis
of three separate mRNA expression platforms with a MWA-
derived protein data set enabled us to better address this
issue. The general lack of correlation between mRNA and
protein levels could be explained biologically by molecular
mechanisms such as mRNA translation efficiency, protein
folding, protein stability, protein assembly into complexes,
transport and localization, or covalent modification, all of
which affect proteins independently from mRNA tran-
scripts. Taken together, our data suggest that cells may
have the capacity to buffer effects on protein that genetic
variation has on mRNA expression levels.
We identified 12 cis and 160 trans pQTLs at an FDR <
0.20 (compared with 11 cis and 0 trans eQTLs at the
same threshold). Although up to two thirds of cis eQTLs
also were also nominally significant cis pQTLs, the major-
ity of cis pQTLs were not nominally significant cis eQTLs.
trans eQTLs and pQTLs did not replicate well across any
platform. This result is consistent with previous studies
that have demonstrated difficulty in reproducing trans
eQTLs across mRNA expression platforms.8,53 However,
16 of 18 of the most significant trans pQTLs (p < 107,
FDR ¼ 0.29) had reproducible effect directions in the
additional cohort of unrelated YRI LCLs that we examined
during the functional validation phase of our project. We
identified similar numbers of cis eQTLs versus cis pQTLs
for the same gene models examined by both platforms
(11 cis eQTLs for 10 genes versus 12 cis pQTLs for 11 genes,
FDR ¼ 0.20), consistent with previously observations
of ~4% of genes having cis eQTLs in the same cohort.26
Consistent with Foss et al.11 in yeast, we identified a larger
number of trans pQTLs than trans eQTLs. These results
suggest that genetic variants affecting mRNA levels tend
to have stronger effects in cis, whereas variants affecting
protein levels tend to have stronger effects in trans. Because
this study is one of the first human studies to publish
on both cis and trans pQTLs, there may truly be more
trans than cis variants affecting the proteome, or thisThe Amerobservation could be biased because of our targeted
quantification of human transcription factors and dis-
ease-related signaling proteins. The observation of an
enrichment of trans, rather than cis, regulatory variants
in complex human diseases such as type 2 diabetes and
glucose homeostasis traits has supported the notion that
many weak trans effects can influence mRNA (and puta-
tively protein) levels and contribute to phenotypic vari-
ability.54 However, we appreciate that the shallower read
depths of the RNA-sequencing data set (~11 million map-
ped reads/individual) could have contributed to reduced
power to detect eQTLs across this population and result
in an underestimate in the proportion of true eQTLs
present.
To assess pQTL reproducibility, we compared our results
with those from a recent pQTL study that consistently
quantified 2,279 proteins by isobaric tandem mass tag-
based quantitative mass spectrometry across LCLs derived
from 74 unrelated individuals from four populations in
the HapMap Consortium.14 None of the 13 pQTLs identi-
fied in the YRI population from the Wu et al.14 study over-
lapped proteins quantified in our study, and two of the
four pQTLs identified in our study at an FDR < 0.05 for
proteins overlapping between both studies were in a
concordant effect direction in the Wu et al. study. Howev-
er, because of the small overlap of proteins (n ¼ 61) and
samples (n ¼ 22) between studies, we do not feel that
these conclusions are sufficient to make any larger infer-
ences about pQTL reproducibility between studies. The
fundamental differences between our approach and that
of Wu et al.14 are in the methodology (mass spectrometry
versus targeted antibody-based methods); the proteins
chosen for measurement (highly abundant proteins de-
tected by the mass spectrometer versus a smaller subset
of targeted transcription factors and disease-related
signaling molecules for which we had high-quality anti-
bodies); and the population (68 YRI individuals versus a
collection of four different ethnic panels with 1–53 indi-
viduals in each). However, 12% of cis and trans pQTLs
identified in LCLs in this study at p < 106 replicate
(here defined as concordant effect direction and nominal
significance) in an unrelated cohort of 129 human cere-
bellum samples of European ancestry (data not shown),
suggesting that many of these pQTLs are indeed real, tis-
sue-independent associations (versus the null expectation
of 2.5% replication).
We replicated a trans pQTL between rs60664312 and
DIDO1 in an additional cohort of unrelated YRI LCLs
and determined that this association was also a cis pQTL
for the tRNA synthetase KARS in the same direction as
DIDO1. We then performed siRNA knockdown on KARS
and observed a concomitant reduction in DIDO1 protein
levels for multiple cell lines. These data suggested that
the trans pQTL for DIDO1 was a strong, reproducible asso-
ciation with a mechanism of action that involved alter-
ation of KARS protein activity. KARS encodes Lysyl-tRNA
synthetase (LysRS), which was originally described toican Journal of Human Genetics 95, 194–208, August 7, 2014 205
catalyze the aminoacylation of lysyl-tRNAs in the cyto-
plasm and mitochondria.55 We hypothesize that RefSeq
NP_001123561.1 (p.Thr623Ser) in LysRS could potentially
affect its ability to be phosphorylated and subsequently its
efficiency to aminoacylate lysyl-tRNAs. Altered KARS pro-
tein levels or function could result in concomitant altered
abundances of downstream proteins such as DIDO1 that
contain codons for this tRNA.
We identified many pQTLs that overlapped SNPs associ-
ated with complex traits and diseases, supporting previous
mechanistic relationships and providing testable hypothe-
ses about functional relationships that require further
investigation. For example, we identified an intronic
pQTL (rs1177283) associated with increased interferon reg-
ulatory factor 5 (IRF5) levels that was previously associated
with increased risk of ulcerative colitis56 (MIM 266600)
and celiac disease57 (MIM 212750). IRF5 is known to
regulate type I interferon response and has been causally
linked to autoimmune disease through variants driving
elevated expression of multiple unique IRF5 iso-
forms.58,59 rs2738459 was previously associated with LDL
cholesterol levels in a population of European descent60
and was associated in our study with ZNF207, a relatively
uncharacterized zinc finger protein. We also identified
many pQTLs that affected not only relative protein levels,
but also the relative protein phosphorylation states,
many of which overlapped with disease-associated loci.
rs16852086 was associated with RPS6 (S240/244) protein
phosphorylation levels in this study and previously with
risk for chronic kidney disease (CKD) in a population of
67,093 Europeans,61 consistent with previous reports of
altered basal RPS6 phosphorylation in CKD-induced
rats.62 pQTLs offer the possibility that causal variants asso-
ciated with complex diseases manifest their effects, at least
in part, by altering protein levels. We suggest that pQTL
analyses may be helpful for gaining additional biological
insight into multidimensional phenotypes that is separate
from that seen when performing eQTL analyses.
Lastly, we have provided a robust and scalable method
for annotating human genetic variation that regulates
the proteome. We demonstrate that meaningful informa-
tion can be gained by a population-level assessment of the
proteome along with the transcriptome. Although we
examined only a subset of the proteome in this study,
our focus on transcription factors will be of great utility
for understanding genetic components of gene expression
regulation by integrating ENCODE TF binding data, and
our approach has no inherent limitation on the numbers
of proteins or individuals that can be examined. Extend-
ing our approach to additional populations, cell types,
and tissues will facilitate the identification of regulatory
variation in complex traits and diseases. Incorporating
this protein-omic data set with other ‘‘omic’’ data sets
will provide a clearer understanding of the links between
complex human traits and diseases with proteins and pro-
vide additional insight into global mechanisms of gene
regulation.206 The American Journal of Human Genetics 95, 194–208, August 7Supplemental Data
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